Report of another critical patient saved by Leronlimab at

New Post Public Reply Private Reply Replies (1) Message Board
Enjay
977
Report of another critical patient saved by Leronlimab at UCLA hospital

Dave Asprey is the host of a podcast called Bulletproof Radio. He interviewed Bill Moses whose Flying Embers lab makes botanical brews (alcohol). Bill had a critical case of Covid and was saved by Leronlimab. I assume it was Dr. Yang but he did not mention the doctor's name. I do not know how long ago he was in the hospital. You can listen to the interview by scrolling down to the middle of the screen at the link below.

https://daveasprey.com/flying-embers-843/

Does anyone know how many patients Dr. Yang saved with Leronlimab? For those not interested in "botanical brews", you can start at 36:15. There is a transcript with the podcast so I pasted below the parts about Leronlimab.


Dave Asprey:
What happened, though, because you got COVID? You got really sick. Tell me about your experience with COVID. This is a real thing. People don't talk about this as much as they should.

Bill Moses:
I didn't grok how impactful COVID could be, I guess, early on. I was taking 10,000 IUs of vitamin D, zinc. I was doing everything, C, astaxanthin. I was healthy. I'm healthy. I'm vibrant. I've got my hyperbaric
chamber. I've got my cryo chamber. I'm doing everything you do. We have a manufacturing facility. We ferment and make our own stuff. We've got a lot of people where we're in mass, but we're essential.
We're essential, so we were able to go to work and work, which was great.
It was one of the great things about being in the food business was we didn't have to be cloistered up in the home, and actually like we're not. So I was part of the community at work and we had someone came in and got it. And several of us got it at the same time. I just doubled down on everything. I waited and got progressively... I started taking ivermectin and was hammering that. Nine, eight days into it, I was literally unable to breathe.
I had my oxygen machine because I pulled it out of my hyperbaric and I'm like... At night I have oxygen in and I'm like, "I don't need to go. I don't need anything." Actually, I was one of those guys that was part of this cohort. There is a cohort of us out there that actually have cytokine storms, and I had a cytokine storm on one of my lungs, where I actually couldn't breathe. I went into UCLA and I was there almost three weeks. After time was going on, the oxygen requirement kept going higher and higher and higher. They
came in, they said, "Do you have a DNR? We're going to have to take you in and intubate you. We can't get any more oxygen in you." At that given time, I was like, "Oh wow, like this is real." So I call my wife, I call my kids. I say goodbye. I literally say goodbye. I do everything I can to... And I realized that there was no more high flow that I could get. I was at the limit.
Just at that time, the head of infectious disease at UCLA comes walking by and comes into my room and says, "Look, we need to probably find an experimental for your treatment." And I was like, "Okay, what?" He told me what he thinks he should give me. He goes, "We've had some success here. I have to call the FDA to get compassionate use for it, because it's not FDA approved." It's still not.

Dave Asprey:
Even though he's a doctor who has a license to do whatever the F he wants, and the FDA is getting in the
way?

Bill Moses:
The FDA will not allow doctors to give anything other than what is approved or what is currently part of their clinicals.

Dave Asprey:
That's an abuse of authority, as a doctor, as a [crosstalk 00:39:30]-

Anyway, so he had to go get special permission. Well, he got it and he came in that night and put two shots of this stuff in me, Leronlimab and

Dave Asprey:
Yeah. [inaudible 00:39:40]-

Bill Moses:
Leronlimab.

Dave Asprey:
Okay.

Bill Moses:
CytoDyn is what is... He had a hunch. He saw it work on several other, and a week later, I was out of the hospital.

Dave Asprey:
That stuff is a mass cell treatment.

Bill Moses:
Yeah, that's right. Yeah. There's some interesting applications on it. It worked for me and I'm thankful for it.

Dave Asprey:
Well, you had a good doctor who was willing to say, "Hmm, I don't know how to treat this virus, but I know how to treat inflammation. And that's what I've been trained to do for years. I'm head of infectious diseases." This is the only pandemic ever where they've forbidden doctors from doing their
work.

Bill Moses:
Well, I mean, I think there's really that the treatments are governed. Hopefully, there's going to be more and more treatments for this, because I think there's a lot of us that'll end up getting it and great treatments are going to help us. So I'm all about treatment, Dave. All about

Dave Asprey:
Treatment is a good thing. It's interesting, the cytokine storm. We know the cytokine that's most common with this is called IL-6. I'm guessing you had high levels of IL-6, right?

Bill Moses:
Yes. Yes.

Dave Asprey:
Did you see the post I wrote in the first two months of pandemic about how to stop IL-6?

Bill Moses:
No, I didn't see it.

Dave Asprey:
No, you didn't because it got taken down.

Bill Moses:
There you go. There you go. Yeah.

Dave Asprey:
Interesting how that works. But there's a bunch of herbals with very potent IL-6-suppressing properties. I know about that because toxic mold people like me who have had mold measures, if we have the genetics for that, we tend to have relatively high IL-6. So I know how to suppress it, and it's not even that hard with botanicals. But apparently talking about that isn't okay. So I didn't. But it's one of those things where I think that when people are using botanicals regularly, that help to regulate inflammation, even if they're drinking, even if they're eating pizza and cheesecake, which is probably not a great idea. Perhaps we can keep a healthy enough balance that we're less likely to get as sick as you did. And like you said, you're in that cohort. It's probably a genetic thing. And it could be an environmental thing where your mass cells were triggered to be more sensitive than others.
But I'm happy you made it. I'm happy you share the story because people say, "Oh, it's not real." Actually, no, there is something going around. It's real. People say, "Oh, I'm invulnerable because I..."
Insert name of health practice. No. You're just more resilient. And there you go. You're sitting here in front of us. You had some resilience and you had good care. Who would have thought? I'm happy you made it.

Bill Moses:
Yeah. Thanks so much. Yeah.

Dave Asprey:
Thanks for sharing your story because there's so much polarization there.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sony's LYTIA 720 Image Sensor: A Game Changer?

Updated Category News Views 58

Unpacking Sony's Latest Sensor: LYTIA 720 Tell me, when was the last time a tech drop made you shake your head in awe? Sony just pulled one of those moves with their latest toy, the LYTIA 720. We're talking a 50-effective megapixel CMOS image sensor crafted for mobile warriors, and it packs a punch that should have the competition looking over their shoulder. Dazzling...

Continue Reading
Infoya Surges with 665% Growth, Wins Fast 50 Spot

Updated Category News Views 43

From Humble Beginnings to High Achiever Alright, let's touch base on Canada's tech landscape for a moment. Infoya's leap into Deloitte's 2026 Technology Fast 50 isn't just a pat on the back—it's a flashing neon sign of what raw ambition mixed with a pinch of AI can cook up for you. They've banked a whopping 665% revenue growth from 2022 to 2025. Not bad for a company...

Continue Reading
Federal Signal Acquires GVS, Boosts Vacuum Truck Lineup

Updated Category News Views 17

Federal Signal's Latest Move in Vacuum Truck Arena A shakeup in the vacuum truck market? You bet. Federal Signal Corporation has made waves yet again by acquiring the lion's share of Global Vacuum Systems (GVS) assets and operations. We're talking a transaction valued at a hefty $29 million. Dishing Out the Dollars and Cents Now, what stirs the pot in this deal is the...

Continue Reading
Beta Bionics Faces Securities Fraud Class Action Challenges

Updated Category News Views 39

The Unexpected Slide of Beta Bionics So your wallet took a bruising with this Beta Bionics deal, eh? It’s another one of those wild tales from the stock jungle where everyone watching the NASDAQ:BBNX action got clipped when reality didn't match the company chest-thumping. Glancy Prongay Wolke & Rotter LLP just laid it out—ripping the Band-Aid off what Beta Bionics...

Continue Reading
2026 Data Integration Stars: User Sentiments Revealed

Updated Category News Views 0

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Continue Reading
Biopharma Rethinks Strategy Amid U.S. MFN Pricing Shift

Updated Category News Views 83

Global Pharma Grapples with U.S. MFN Pricing Sometimes, regulatory changes hit the industry like a freight train, and other times they creep in like the tide reshaping everything without much fanfare. The U.S. Most-Favored-Nation (MFN) pricing rule, spotlighted in a recent World ACCESS Consortium (WAC) white paper, might be the latter. It’s bending biopharmaceuticals'...

Continue Reading
Ecopetrol Sets Q3 2026 Results Release, Conference Call

Updated Category News Views 110

Big Day Incoming: Ecopetrol's Q3 Results Alright, folks, buckle up because Ecopetrol is about to drop its third-quarter numbers for 2026. On November 10th, after the bell, Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) will lift the veil on its financial and operational performance. Make sure you got your calendars marked, and better yet, your browser's up to date. Nothing's...

Continue Reading
Smartpress: Adobe & Canva Shape Print Design World

Updated Category News Views 54

Adobe's Stranglehold on Professional Design Over at Smartpress, they've pulled the curtain back on just how heavily Adobe Creative Suite weighs in on the print design sector. The company's recent analysis shines a light on the staggering 66% dominance of Adobe's InDesign and Illustrator in file submissions. That's a hefty portion influencing both the quality and financial...

Continue Reading
First Responders Honored in Times Square Hero Ceremony

Updated Category News Views 56

Stepping up to Spotlight Courage In a world that often seems to teeter on chaos, it's those unsung heroes—the first responders—who stand ready to turn panic into repose. October 28th saw Times Square in New York City transform into a beacon of appreciation as the First Responders Children's Foundation (FRCF) applauded nineteen fearless foes of danger. Picture that...

Continue Reading
Uwharrie Capital's 2026 Q3 Shows Steady Growth

Updated Category News Views 11

Uwharrie Capital's Financial Dance Well, don't dust off the neon ticker tape quite yet but Uwharrie Capital Corp (OTCQX:UWHR) gave us a reason to nod approvingly over our espresso this quarter. From a scrappy hometown operation to a regional bank showing its mettle, the numbers they've laid down ain't half bad. Assets Climb a Billion-Dollar Ladder First thing that jumps...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Push Charles Schwab Options Amid Market Speculations

Updated Category News Views 231

Investors Show Caution with Charles Schwab Options Amid Market Speculations Investors seem to be taking a measured approach when it comes to Charles Schwab (NYSE: SCHW). They've been actively engaged in options trading, which isn't going unnoticed. Recent analysis suggests that some of the big players in finance are leaning towards a more bearish outlook, hinting at...

Continue Reading
Premier Truck Rental Introduces Compact Crane Add-On Option

Updated Category News Views 70

Introducing Premier Truck Rental's New Crane Add-On Premier Truck Rental (PTR) is excited to unveil its latest enhancement to its upfit offerings: a compact crane add-on. This innovative solution features a 4-foot crane with a maximum load capacity of 900 pounds, designed to address a variety of lifting needs across different applications. Fleet managers now have the...

Continue Reading
Jim Cramer's Investment Insights: Focus on Lam Research and More

Updated Category News Views 65

Investing Insights from Jim Cramer In a recent episode of CNBC's “Mad Money Lightning Round,” investment expert Jim Cramer highlighted a few key stocks to watch in the current market landscape. His notable recommendation was for investors to consider Lam Research Corporation (NASDAQ: LRCX), expressing his strong approval. Cramer stated, “I like it very much here,”...

Continue Reading
Revolutionizing Case Preparation with AAAi Chat Book Launch

Updated Category News Views 103

Introduction to AAAi Chat Book The American Arbitration Association (AAA) and its international division, the International Centre for Dispute Resolution (ICDR), have introduced an innovative tool aimed at transforming the way cases are prepared and presented. The launch of the AAAi Chat Book Case Preparation and Presentation marks a significant milestone in the field of...

Continue Reading
Richtech Robotics’ AI Robot ADAM Showcases Innovation at VIP Gala

Updated Category News Views 109

Richtech Robotics’ ADAM Robot to Shine at Exclusive Event Richtech Robotics Inc. (Nasdaq: RR) has announced that its advanced robot, ADAM, is set to make a captivating appearance at a prestigious event focused on space exploration. This invitation-only affair will showcase the robot's unique ability to serve space-themed cocktails, adding a fun twist to the gathering....

Continue Reading